SCHEMBL150029

SCHEMBL150029

O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O2)cc1Br

nearest known ligand 0.63

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TYMS P04818 4/20 0.62
POLB P06746 2/20 0.61
POLA1 P09884 1/20 0.59
POLD1 P28340 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Triphosphate SCHEMBL7631515 1.00 TYMS (0.62) TYMSPOLBPOLA1POLD1
SCHEMBL1163795 1.00 TYMS (0.62) TYMSPOLBPOLA1POLD1
SCHEMBL13551342 1.00 TYMS (0.62) TYMSPOLBPOLA1POLD1
SCHEMBL15810821 1.00 TYMS (0.62) TYMSPOLBPOLA1POLD1
SCHEMBL3235048 0.90 TYMS (0.74) TYMS
SCHEMBL17117806 0.90 TYMS (0.74) TYMS
SCHEMBL335865 0.90 TYMS (0.74) TYMS
SCHEMBL6462543 0.89 POLB (0.62) TYMSPOLBPOLA1POLD1
SCHEMBL149769 0.89 POLB (0.62) TYMSPOLBPOLA1POLD1
SCHEMBL12758590 0.89 TYMS (0.63) TYMSPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250263766-A1 NUCLEIC ACID AND GENE SYNTHESIS NunaBio Limited (GB) 2025-08-21 US claimed
US-20250210148-A1 METHOD OF PRODUCING DATA-ENCODED NUCLEIC ACID AND NUCLEIC ACID PRODUCED BY THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2025-06-26 US claimed
EP-4536855-A1 NUCLEIC ACID AND GENE SYNTHESIS NunaBio Limited (GB) 2025-04-16 EP claimed
EP-4481057-A1 SAMPLE PREPARATION METHODS USING MODIFIED BASES FOR RAPID IDENTIFICATION AND SEQUENCING Depixus (FR) 2024-12-25 EP claimed
US-20240309447-A1 METHODS AND KITS FOR PREPARING A SAMPLE COMPRISING ONE OR MORE RNA MOLECULES FOR SEQUENCING THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2024-09-19 US claimed
WO-2023237889-A1 NUCLEIC ACID AND GENE SYNTHESIS NunaBio Limited (GB) 2023-12-14 WO claimed
US-10799602-B2 Method for increasing expression of RNA-encoded proteins CUREVAC AG (DE) 2020-10-13 US claimed
US-10293060-B2 Method for increasing expression of RNA-encoded proteins CUREVAC AG (DE) 2019-05-21 US claimed
US-20190100784-A1 RNA ANALYSIS BY TOTAL HYDROLYSIS CureVac SE (DE) 2019-04-04 US claimed
EP-3423595-A1 RNA ANALYSIS BY TOTAL HYDROLYSIS CureVac AG (DE) 2019-01-09 EP claimed
US-7488577-B2 non-radioactive assay in microtiter plate format enabling colorimetric or fluorimetric product detection for drug screening; solid phase synthesis CAVIDI TECH AB (SE) 2009-02-10 US claimed
EP-1395675-B1 A METHOD FOR MEASURING DNA POLYMERIZATION AND APPLICATIONS OF THE METHOD CAVIDI TECH AB (SE) 2006-01-18 EP claimed
US-20040157230-A1 Method for measuring dna polymerization and applications of the method CAVIDI AB (SE) 2004-08-12 US claimed
US-20030039976-A1 Methods for base counting PE CORPORATION (NY) 2003-02-27 US claimed
US-5985266-A SENSITIZE TUMORS, RETROVIRUS COMPRISES OPERATIVELY LINKED TO A PROMOTER A GENE ENCODING A VIRAL THYMIDINE KINASE; SUCH THAT SAID TUMOR CELLS BECOME TRANSDUCED BY SAID RETROVIRUS AND EXPRESS SAID VIRAL THYMIDINE KINASE GENE; HUMAN GENE THERAPY RESEARCH INSTITUTE (US) 1999-11-16 US claimed
EP-4747380-A1 MODULATING EXPRESSION OF ALAS1 (5'-AMINOLEVULINATE SYNTHASE 1) GENE CRISPR Therapeutics AG (CH) 2026-05-27 EP disclosed
WO-2026103936-A1 CHEMICALLY MODIFIED CIRCULAR RNA MOLECULE, PREPARATION METHOD THEREFOR, AND USE THEREOF 上海元码智药生物技术有限公司 2026-05-21 WO disclosed
US-4749647-A Polymerization-induced separation assay using recognition pairs GENETIC SYSTEMS CORPORATION (US) 1988-06-07 US disclosed
US-4699876-A ZYMOGEN ACTIVATED ENZYMATIC REACTION CASCADE TO DETECT HYBRIDS E. I. DU PONT DE NEMOURS AND COMPANY (US) 1987-10-13 US disclosed
EP-0151001-A2 Nonradiometric polynucleotide probes E.I. DU PONT DE NEMOURS AND COMPANY (US) 1985-08-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10293060-B2 Method for increasing expression of RNA-encoded proteins STING1, UPF1, CUTA TYMS 2618/4885POLB 273/4885POLA1 291/4885
US-10799602-B2 Method for increasing expression of RNA-encoded proteins STING1, UPF1, CUTA TYMS 2618/4885POLB 273/4885POLA1 291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.